Skip to main content

For adults with moderate to severe hidradenitis suppurativa

Purple to pink gradient background

Looking for an HS treatment with proven experience?

1st

COSENTYX is the first treatment of its kind that targets IL-17A, a molecule thought to play a role in causing inflammation that contributes to HS symptoms. The way COSENTYX works in the body and how it affects HS symptoms is not fully known.

3.7+ MILLION

Before the FDA approved COSENTYX to treat adults with moderate to severe HS, over 3.7 million COSENTYX prescriptions had been filled in the United States across all indications combined (not including HS).

16 YEARS

COSENTYX has been extensively studied for over 16 years across 8 conditions.

COSENTYX targets and blocks IL-17A, a molecule thought to play a role in the inflammation that may contribute to HS symptoms.

As of March 2023.

COSENTYX has had a well-studied safety profile since its launch in 2015 and has been approved to treat numerous conditions: 

2015 — adults with moderate to severe plaque psoriasis   
2016 — adults with active ankylosing spondylitis and active psoriatic arthritis   
2020 — adults with active non-radiographic axial spondyloarthritis   
2021 — children with plaque psoriasis (6 years and older), psoriatic arthritis (2 years and older), and enthesitis-related arthritis (4 years and older)  
2023 — adults with moderate to severe hidradenitis suppurativa

*Limitations apply. Valid only for those with private insurance. Program provides up to $16,000 annually for the cost of COSENTYX and up to $150 per infusion (up to $1,950 annually) for the cost of administration. Co-pay support for infusion administration cost not available in Rhode Island or Massachusetts. Offer not valid under Medicare, Medicaid, or any other federal or state program. Novartis reserves the right to rescind, revoke, or amend this program without notice. See complete Terms & Conditions for details.